AI in the Prediction of Hepatic Fibrosis Progression Using Non-Coding RNAs
Clinica Chimica Acta · 2026-05 · 587 · 120973
DOI: 10.1016/j.cca.2026.120973 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinica Chimica Acta, 2026-05. Verfasst von Dibakar Roy und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Chemical Biology, Indiana University, Indianapolis, Indiana, 47405, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Artificial Intelligence, RNA, Untranslated. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 143 Literaturangaben.
Abstract (Originalsprache)
Hepatic fibrosis is a dynamic and progressive condition, which can lead to cirrhosis and hepatocellular carcinoma (HCC) when not treated. Appropriate assessment of the disease progression of fibrosis is critical to the early intervention and individualized treatment regimens. Traditional biopsy techniques are invasive and prone to sampling error and requires development of less invasive predictive techniques. Non-coding RNAs (ncRNAs) including those miRNAs (miRNAs), long ncRNAs (lncRNAs), and circular RNAs (circRNAs) have emerged as key regulators of hepatic fibrogenesis, and as a possible biomarker to disease staging and prognosis. The emergence of artificial intelligence (AI) and machine learning (ML) and deep learning (DL) in particular has revolutionized the comprehensive large-scale analysis of transcriptomic data, enhancing the identification of biomarkers of ncRNAs and predictive modeling. The AI-based algorithms have been found to be more precise in anticipating fibrosis progression by means of integrating multi-omics data, ncRNA interaction networks, and by improving non-invasive diagnostic instruments. This review involves the analysis of AI and ncRNA research in hepatic fibrosis, recent discoveries, possible challenges, and future opportunities. We address the necessity of standardization of data and clinical validation as well as discuss the role of AI in identifying biomarkers of ncRNA, predicting the stage of fibrosis and risk stratification. ncRNA analysis with AI has a tremendous potential of transforming the diagnostics and prognostics of hepatic fibrosis, enabling precision hepatology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Chemical Biology, Indiana University, Indianapolis, Indiana, 47405, USA.
- Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun 248007, Uttarakhand, India.. Electronic address: sadiquehussain007@gmail.com.
- Institute of Biotechnology and Genetic Engineering (Health Division), The University of Agriculture, Peshawar 25000, Khyber Pakhtunkhwa, Pakistan.
- Faculty of Pharmacy, Gokul Global University, Sidhpur, Gujarat 384151, India.
- Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman 19328, Jordan.
- University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab 140413, India.
Zitieren
APA
Roy, D., Hussain, M. S., Khan, Y., Patel, D. N., Smerat, A., Bainsal, N., Ashique, S., Kumar, A., Khan, I. A., Dilorom, O., Allaberganova, M., & Ashirova, A. (2026). AI in the Prediction of Hepatic Fibrosis Progression Using Non-Coding RNAs. Clinica Chimica Acta, 587, 120973. https://doi.org/10.1016/j.cca.2026.120973
Vancouver
Roy D, Hussain MS, Khan Y, Patel DN, Smerat A, Bainsal N, et al. AI in the Prediction of Hepatic Fibrosis Progression Using Non-Coding RNAs. Clinica Chimica Acta. 2026;587:120973. doi:10.1016/j.cca.2026.120973
BibTeX
@article{Roy2026,
author = {Roy, Dibakar and Hussain, Md Sadique and Khan, Yumna and Patel, Dhara N and Smerat, Aseel and Bainsal, Neeraj and Ashique, Sumel and Kumar, Arun and Khan, Irfan Ali and Dilorom, Ochilova and Allaberganova, Muyassar and Ashirova, Anorgul},
title = {AI in the Prediction of Hepatic Fibrosis Progression Using Non-Coding RNAs},
journal = {Clinica Chimica Acta},
year = {2026},
volume = {587},
pages = {120973},
doi = {10.1016/j.cca.2026.120973}
}
EUVIMED